Restoring Balance In The Gut To Prevent Drug-Resistant Infection
Silvia Caballero, one of In Vivo’s 2020 Rising Leaders, is heading up Vedanta’s efforts to prevent potentially lethal infections stemming from colonization of the gut microbiome with a novel bacterial cocktail that is nearing clinical development.
You may also be interested in...
Vedanta’s latest financing allows it to push three of its microbiome-based drug candidates further into the clinic, with big name partners such as BMS and Janssen onboard.
Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.